30.09.2010 13:02
BlackSwan Pharma announced today exciting news concerning its development candidate CD-160130 resulting from its recent collaboration with Professor Annarosa Arcangeli of the Department of Experimental Pathology and Oncology at the University of Florence (Italy). These findings demonstrate for the first time that selective inhibition of hERG1 channel isoforms can be achieved and may represent an important milestone since the targeting of hERG1 in tumour cells can be seen as a means to both induce apoptosis and also to overcome the resistance to classical chemotherapeutic drugs used for the treatment of leukaemias.
Read more … CD-160130 – a selective tumour hERG channel inhibitor
07.08.2009 16:23
Leipzig. BlackSwan Pharma GmbH, a developer of small molecule agents for the treatment of chronic lymphocytic leukaemia, announced today that the company will present its drug candidate CD-160130 at the poster session on new substances at the German CLL Study Group´s 22nd Work Meeting in Kiel, 25/26 September 2009.
Read more … BlackSwan Pharma to present its drug candidate CD-160130
26.06.2009 17:55
Leipzig. The biopharmaceutical company BlackSwan Pharma GmbH disclosed today that Professor Clemens Wendtner is to commence a councelling role with the company. Professor Wendtner is Full Professor of Medicine and Assistant Medical Director at the Clinic I for Internal Medicine based at the University of Cologne directed by Professor Michael Hallek. Notably, Professor Wendtner is both Secretary of the German CLL Study Group and a member of the society´s Strategic Steering Committee. By engaging Professor Wendtner, BlackSwan Pharma has once again proved its ability to attract important key figures enabling it to progress with the development of CD-160130, a novel small molecule apoptosis promoter for the treatment of chronic lymphocytic leukaemia (CLL)
Read more … CLL expert advising with BlackSwan Pharma
23.04.2009 22:11
Leipzig. The biopharmaceutical company BlackSwan Pharma GmbH, dedicated to the profiling and pre-clinical development of novel agents for the treatment of haematological cancers, announced today that its consulting team has been further strengthened by the appointment of Dr. Ulrich Granzer. The inclusion of Dr. Granzer into the team highlights the wealth of experience being gathered by BlackSwan Pharma GmbH to drive their development of CD-160130.
Read more … Dr. Ulrich Granzer appointed
23.04.2009 13:22
Leipzig. The biopharmaceutical company BlackSwan Pharma GmbH, dedicated to the profiling and pre-clinical development of novel agents for the treatment of haematological cancers, announced today that the company has been strengthened by the appointment of Dr. Kenneth Mugridge into its consulting team. Dr. Mugridge has accumulated more than 30 years experience in pre-clinical drug discovery and development within pharmaceutical companies in the United Kingdom, Italy and Germany.
Read more … Dr. Kenneth Mugridge appointed
